期刊文献+

唑来膦酸为主治疗乳腺癌骨转移骨痛40例疗效观察 被引量:3

The curative effect of diphosphate on bony metastasis and ostalgia from 40 cases of breast cancer
下载PDF
导出
摘要 目的探讨以唑来膦酸为主治疗乳腺癌骨转移骨痛的临床疗效。方法选择新疆医科大学附属肿瘤医院2005年6月—2010年6月晚期有骨转移的乳腺癌患者40例,其中单纯使用唑来膦酸治疗20例(单纯组),联合放化治疗20例(联合放化组)。用唑来膦酸4mg溶于生理盐100mL中,静脉滴注15min以上,每4周1次,共2~4个周期,同时对有化疗及放疗指征者用唑来膦酸治疗第3d后开始化、放疗,以完全缓解(CR)、部分缓解(PR)、轻度缓解(MR)及无效(NR)来评估疗效。结果全组40例,CR9例,PR21例,MR7例,NR3例,总有效率为75%,其中单纯使用唑来膦酸20例,CR4例,PR10例,有效率为70%,唑来膦酸联合使用化、放疗20例,CR5例,PR11例,有效率为80%。全组病例不良反应主要为发热(20例),8例出现肌肉酸痛和骨痛加重现象。结论第3代双膦酸盐唑来膦酸对晚期骨转移痛所致骨痛疗效确切,使用安全,合并使用化、放疗的病例中,止痛疗效较好。 Objective To investigate the curative effect of diphosphate on bony metastasis and ostalgia of breast cancer.Methods From june 2005 to june 2010,40 cases of breast cancer from the affiliated tumor hospital of Xinjiang medical university that have bony metastasis and ostalgia with the treament of diphosphate were analyzed retrospectively.We evaluate the curative effect with CR,PR,SR and invalid after diphosphate treatment that put 4 mg into 100 mL 0.9% NaCl,intravenously guttae more than 15 mins every four weeks about 2~4 cycles even by radiotherapy or chemotherapy after three days with diphosphate treatment.Results Of the 40 patients,the cases of CR,PR,MR,NR were 9,21,7 and 3 retrospectively,and the total effective rate was 75%.Of the 20 cases which only used diphosphate,the cases of CR and PR were 4 and 10 retrospectively,of the 20 cases which used diphosphate and radiotherapy or chemotherapy,the cases of CR and PR were 5 and 11,and the total effective rate was 80%.And in the most of adverse reactions,20 cases were fever,8 cases were muscle pain and aggravated bone pain.Conclusion The curative effect of third generation diphosphate is obviously safe for ostalgia from augmentation and even more than single-use diphosphate compare with combining radiotherapy or chemotherapy.
出处 《新疆医科大学学报》 CAS 2011年第11期1262-1264,1267,共4页 Journal of Xinjiang Medical University
关键词 唑来磷酸 乳腺癌 骨转移 diphosphate breast cancer bony metastasis
  • 相关文献

参考文献10

  • 1Filzgarald RH,Kaufer H,Malkani A.Orthopaedics[M].London:Mos-by Inc,2002:1078-1088.
  • 2Akhtari M,Mensuri J,Newman KA,et al.Biology of breast cancer bone metastasis[J].Cancer Biol Ther,2008,7(1):3-9.
  • 3Coronado M,Redondo A,Coya J,et al.Clinical role of Sm-153 EDTMP in the treatment of painful bone metastatic disease[J].Clin Nucl Med,2006,31(10):605-610.
  • 4Mundy GR.Metastasis to bone:causes,consequences and therapeutic opportanities[J].Nat Rev Cancer,2002,2(8):584-593.
  • 5Vander-Linden YM,Dijkstra SP,Vonk EJ,et al.Prediction of survival in patients with metastases in the spinal column:resuits based on a randomized trial of radiotherapy[J].Cancer,2005,103(2):320-328.
  • 6Luckman SP,Hughes DE,Coxon FP,et al.Nitrogen-containing bisphosphonates inhibit the mevalonate path way and prevent poat translational prenylation of GTP-binding proteins,including Ras[J].J Bone Miner Res,1998,13:581-589.
  • 7Hughes DE,Wright KR,Uy HL,et al.Bisphosphonates promote apoptosis in murine osteoclasts in vitro and invixo[J].J Bone Miner Res,1995,10:1478-1487.
  • 8Ferretti G,Fabi A,Carlini P,et al.Zoledronic-acidinduced circulating level modifications of angiogenicfactors,metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients[J].Oncology,2005,69(1):35-43.
  • 9Yamada K,Kohno N.Efficacy of bisphosphonatesfor bone paincontrol[J].Nippon Rinsho,2007,65(1):152-156.
  • 10马剑波,顾红梅,郁玮玮,陈不尤,季斌.唑来膦酸联合放疗治疗骨转移癌55例[J].肿瘤研究与临床,2009,21(4):264-266. 被引量:7

二级参考文献8

  • 1牛润桂.唑来膦酸治疗癌性骨转移疼痛的有效性和安全性研究[J].肿瘤研究与临床,2007,19(2):122-124. 被引量:3
  • 2Porter AT, Fontanesi J. Palliative irradiation for bone metastasis: a new paradigm. Int J Radiat Oncol Biol Phys, 1994, 29:1199-1200.
  • 3Rosen LS, Gordon D, Kaminski M, et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complication in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer, 2003, 98: 1735-1744.
  • 4Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with non small cell lung carcinoma and other solid tumors: a randomized phase In ,double-blind, placebo-controlled trial. Cancer, 2004, 100: 2613-2621.
  • 5Ural AU, Avcu F, Candir M, et al. In vitro synergistic cytoreductive effects of Zoledronic acid and radiation on breast cancer cells. Breast Cancer Res, 2006, 8: R52.
  • 6Arrington SA, Damron TA, Mann KA, et al. Concurrent administration of zoledronic acid and irradiation leads to improves bone density, biomechanical strength and microarchitecture in a mouse model of tumor-induced osteolysis. J Surg Oncol, 2008, 97: 284-290.
  • 7Kohno N. Treatment of breast cancer with bone metastasis: bisphosphonate treatment-current and future. Int J Clin Oncol, 2005, 13: 18-23.
  • 8Coleman RE. Emerging strategies in bone health management for the adjuvant patient. Semin Oncol, 2007, 34:S11-16.

共引文献6

同被引文献23

  • 1孙征,束永前.唑来膦酸对肺癌细胞生长抑制的观察及机制的初步研究[J].临床肿瘤学杂志,2006,11(6):457-460. 被引量:8
  • 2高云生,应红梅,熊小鹏,胡超苏.局部晚期鼻咽癌放疗与化疗综合治疗的生存分析[J].中华放射肿瘤学杂志,2007,16(4):241-244. 被引量:29
  • 3Chang ET, Adami HO. The enigmatic epidemiology of naso- pharyngeal carcinoma[J]. Cancer Epidemiol Biomarkers Prev, 2006,15 (10) : 1765-1777.
  • 4Schneider A, Kalikin LM, Mattos AC, et al. Bone turnover mediates preferential localization of prostate cancer in the skeleton[J]. Endocrinology, 2005,146(4): 1727-1736.
  • 5Razak AR, Siu LL, Liu FF, et al. Nasopharyngeal carcinoma: the next challenges[J]. Eur J Cancer,2010,46(11) : 1967- 1978.
  • 6Bensouda Y, Kaikani W, Ahbeddou N, et al. Treatment for metastatic nasopharyngeal earcinoma[J]. Eur Ann Otorhino- aryngol HEad Neck Dis, Z0l1,1Zg(2) :79-85.
  • 7Jahanzeb M, Hirsh V. Bisphosphonates in lung cancer: more than a palliative therapy? [J]. $emin Oncol,2010,37(Supp 1) : 45- 52.
  • 8Kingsley LA, Fournier PG, Chirgwin JM, et al . Molecular biology of bone metastasis [J]. Mol Cancer Ther, 2007, 6 (10) :2609-2617.
  • 9Saad F,Schindler F, Lajolo PP, et al. New research findings on zoledronic acid: survival, pain, and anti-tumour effects [J]. Cancer Treat Rev,2008,34(2) :183- 192.
  • 10Kavanagh KL, Guo K, Dunford JE, et al. The molecular mechanism oi" nitrogen-containing bisphosphonates as antios teoporosisdrugs[J]. Proc Natl Acad Sci USA, 2006,103: 7829 -7834.

引证文献3

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部